良性前列腺增生微创手术治疗对性功能影响的系统评价与荟萃分析
该系统评价与荟萃分析检索Ovid、Embase和Medline/PubMed数据库,纳入77项研究共11477例患者,评估Rezum、Urolift、PAE、iTIND、Optilume和TPLA等微创手术治疗良性前列腺增生对勃起和射精功能的影响。汇总分析显示Rezum和Urolift术后IIEF评分显著改善,Urolift显著改善MSHQ功能与困扰评分,Rezum仅改善MSHQ困扰评分,PAE、iTind、Optilume和TPLA对勃起或射精功能无显著影响。
要点
- Rezum和Urolift术后IIEF评分显著改善
- Urolift改善MSHQ功能与困扰评分,Rezum仅改善困扰评分
- PAE、iTind、Optilume和TPLA对性功能无显著影响
核心结论
- 微创手术是希望维持性功能的良性前列腺增生患者的有前景选择,可保留甚至改善勃起和射精功能。
研究设计与样本
- 系统评价与荟萃分析,2025年5月检索Ovid、Embase和Medline/PubMed数据库,最终纳入77项研究共11477例患者。
主要发现
- 汇总分析显示Rezum和Urolift术后IIEF评分显著改善。
- Urolift显著改善MSHQ功能评分和困扰评分,Rezum仅改善MSHQ困扰评分。
- PAE、iTind、Optilume和TPLA对勃起或射精功能无显著影响。
关键数值与推荐
- 纳入标准为英文文献、评估微创手术、包含性功能结局;排除汇总分析、无全文摘要和未完成临床试验。
- 纳入的微创手术包括水蒸气热疗(Rezum)、前列腺尿道提升术(Urolift)、前列腺动脉栓塞术(PAE)、临时植入式镍钛装置(iTIND)、Optilume BPH导管系统和经会阴激光消融术(TPLA)。
- 勃起功能采用国际勃起功能指数(IIEF)评分评估,射精功能采用男性性健康问卷(MSHQ)评估。
临床怎么用
- 对于关注性功能的良性前列腺增生患者,可优先考虑Rezum或Urolift以保留或改善勃起和射精功能。
- PAE、iTind、Optilume和TPLA对性功能无显著影响,可作为不期望性功能变化的患者的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) can significantly impair a man's quality of life. While traditional surgical treatments are effective, they often pose risks to sexual function, particularly in the form of ejaculatory and/or erectile dysfunction. Minimally invasive surgical treatments (MISTs) have emerged as alternative procedures that aim to alleviate LUTS while preserving sexual function. OBJECTIVE: Investigate the impact of MISTs for BPH on sexual function including erectile and ejaculatory function. METHODS: In May 2025, a systematic review and meta-analysis of sexual function outcomes in MISTs was performed using the Ovid, Embase, and Medline/PubMed databases. Articles were included if they were in English, assessed a MIST, and incorporated sexual function outcomes. Articles were excluded if they included pooled analyses, were abstracts without full text, and/or were ongoing incomplete clinical trials. We included studies on water vapor thermal therapy (Rezum), prostatic urethral lift (Urolift), prostatic artery embolization (PAE), temporary implantable nitinol device (iTIND), Optilume BPH catheter system, and transperineal laser ablation (TPLA). Outcomes included erectile function using International Index of Erectile Function (IIEF) scores and ejaculatory function using the Male Sexual Health Questionnaire (MSHQ). RESULTS: The initial search yielded 2646 studies. After screening and full text review, 77 studies met inclusion criteria encompassing a total of 11,477 patients. Based on the pooled analyses, IIEF scores significantly improved after Rezum and Urolift. Urolift significantly improved MSHQ-function and bother scores, while Rezum only improved MSHQ-bother scores. PAE, iTind, Optilume, and TPLA did not significantly impact erectile or ejaculatory function. CONCLUSIONS: MISTs are a promising option for management of BPH in patients interested in maintaining sexual function, preserving or even improving erectile and ejaculatory function.
引用
- Cahill EM, Lindenbaum MM, Estright A, et al. The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2026. PMID: 41776214. doi:10.1038/s41391-026-01091-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。